HOME >> MEDICINE >> NEWS
Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit

ss III or IV angina refractory to medical therapy who also had multivessel occlusive coronary artery disease not amenable to revascularization. Patients were treated in dose-escalating fashion at 200, 800 or 2,000 mg dose, injected directly into the heart muscle with a hypodermic needle after a mini-thoracotomy, a surgical incision in the chest wall.

Patients were followed for clinical events after one year by hospital records, follow-up visits or telephone contact. At the most recent follow-up, no patients had Class IV angina, and only three (11.5%) had Class II angina, while the remaining had Class I or II angina. Compared to baseline, average angina class decreased from 3.6 0.5 to 1.3 1.0 after the first year. This benefit persisted to 24 months when the mean angina class was 1.5 1.2 (p< 0.05).

Major clinical events such as death, myocardial infarction (MI, or heart attack) and repeat revascularization were uncommon during the first year but more frequent after one year at a rate consistent with the severity of the underlying disease in a population with advanced atherosclerosis. The majority of events were the result of progression of disease in areas of the heart remote from the site of injection.

Previous Clinical Data

Physicians who participated in the Phase I study published previous reports stating that the results demonstrated the safety of VEGF-2 and citing significant improvement in the exercise tolerance time in all dose groups. The study reports reflected that 80% of the patients treated experienced an improvement (decrease) in angina class of two or more levels and 40% of the patients experienced complete elimination of angina symptoms. Similarly, significant reductions in the number of angina episodes per week and the number of nitroglycerin tablets taken were observed. Given the invasive nature of this trial, there was not a control group that received a placebo.

The Phase I trial was followe
'"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Burns McClellan
8-Mar-2005


Page: 1 2 3 4 5

Related medicine news :

1. Many children are undervaccinated or have delayed vaccinations in their first 2 years of life
2. 14-year study finds that quitting smoking adds years to life
3. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
4. Cumulative trauma in adulthood can worsen health in later years
5. Malnutrition in early years leads to low IQ and later antisocial behavior, USC study finds
6. Vioxx should have been withdrawn 4 years ago
7. Cancer burden seen even many years after diagnosis
8. Scientists meet to review Envisat results after two and a half years of operations
9. Study finds lung transplants increase survival of cystic fibrosis patients by more than four years
10. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years
11. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... , ... January 20, 2017 , ... "TransFlare 4K Mystique ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have ...
(Date:1/20/2017)... ... ... fine examination of how God handles sin, including how to let go of lingering guilt ... over ten long years has been waiting to release this powerful insight about forgiveness that ... serving the Lord for over twenty years, and he has been preaching and teaching the ...
(Date:1/20/2017)... ... , ... “The Land of More and More”: a brilliant story for ... shares the simple and achievable answer. “The Land of More and More” is the ... Church in Angola, Indiana where he works with the children’s ministry department. , ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy Network ... of their 503A compounding pharmacy located in Ocala, Florida. , Meeting the ... patients throughout the United States for high-quality human anti-aging and wellness compounded ...
(Date:1/19/2017)... Melville, New York (PRWEB) , ... January 19, ... ... state–of-the-art high definition dynamic telemedicine solutions, has recently unveiled impressive transportable capabilities with ... this newly designed product is an extension to RMT technology that delivers HD, ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... CLEVELAND , Jan. 19, 2017 ViewRay, ... (DFG), a federal institution supporting research in ... installation and patient treatments at the University Clinic Heidelberg ... The MRIdian Linac program will be headed ... who also heads radiation oncology at the German Cancer ...
(Date:1/19/2017)... Florida , January 19, 2017 ... Trump administration appears serious about reducing the FDA,s ... and innovation in the medical drug industry, many ... ahead with new clinical trials and development of ... companies forging ahead with recent developments include:  Moleculin ...
(Date:1/19/2017)... , Jan. 18, 2017  Magnetic Insight Inc., ... entered into an agreement with inviCRO LLC to ... MPI imaging system based on inviCRO,s VivoQuant™ visualization ... distributed as a complete MPI solution package with ... nanoparticle or cell imaging in vivo. ...
Breaking Medicine Technology:
Cached News: